Turnover: ()

Country: France

Paris-listed French biotech startup


Abivax: French biotech nugget on track to raise 250 million euros on Wall Street 21/10/2023

  • Abivax is a French biotechnology company specializing in chronic inflammatory diseases.
  • Abivax plans to raise 250 million euros through a dual listing on the US stock exchange and a private placement in Europe, in addition to the 280 million euros raised since the beginning of the year.
  • The potential market for Obefazimod, a drug candidate for treating ulcerative colitis, is estimated at between $5 and $10 billion.
  • 70% of sales in inflammatory diseases are generated in the United States.